Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Botulinum toxin type A in, treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial
Autore:
Naumann, M; Lowe, NJ;
Indirizzi:
Univ Wurzburg, Dept Neurol, D-97080 Wurzburg, Germany Univ Wurzburg Wurzburg Germany D-97080 Neurol, D-97080 Wurzburg, Germany Cranley Clin Dermatol, London W1M 9AD, England Cranley Clin Dermatol London England W1M 9AD ol, London W1M 9AD, England
Titolo Testata:
BRITISH MEDICAL JOURNAL
fascicolo: 7313, volume: 323, anno: 2001,
pagine: 596 - 599
SICI:
0959-535X(20010915)323:7313<596:BTTAIT>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
PALMAR HYPERHIDROSIS; FOCAL HYPERHIDROSIS; ENDOSCOPIC SYMPATHECTOMY; A TOXIN; INJECTION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Naumann, M Univ Wurzburg, Dept Neurol, Josef Schneider Str 2, D-97080 Wurzburg, Germany Univ Wurzburg Josef Schneider Str 2 Wurzburg Germany D-97080y
Citazione:
M. Naumann e N.J. Lowe, "Botulinum toxin type A in, treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial", BR MED J, 323(7313), 2001, pp. 596-599

Abstract

Objectives To evaluate the safety and efficacy of. botulinum toxin type A in the treatment of bilateral primary axillary hyperhidrosis. Design Multicentre, randomised, parallel group, placebo controlled trial. Setting 17 dermatology and neurology clinics in Belgium, Germany, Switzerland, and the United Kingdom. Participants Patients aged 18-75 years with bilateral primary axillary hyperhidrosis sufficient to interfere with daily living. 465 were screened, 320 randomised, and 307 completed the study. Interventions Patients received either botulinum toxin type A (Botox) 50 U per axilla or placebo by 10-15 intradermal injections evenly distributed within the hyperhidrotic area of each axilla, defined by Minor's iodine starch test. Main outcome measures Percentage of responders (patients with greater thanor equal to 50% reduction from baseline of spontaneous axillary sweat production) at four weeks, patients' global assessment of treatment satisfaction score, and adverse events. Results At four weeks, 94% (227) of the botulinum toxin type A group had responded compared with 36% (28) of the placebo group. By week 16, response rates were 82% (198) and 21% (16), respectively. The results for all other measures of efficacy were significantly better in the botulinum toxin groupthan the placebo group. Significantly higher patient satisfaction was reported in the botulinum toxin type A group than the placebo group (3.3 v 0.8,P < 0.001 at 4 weeks). Treatment related adverse events were reported by only 27 patients (11%) in the botulinum. toxin group and four (5%) in the placebo group (P=0.13). Conclusion Botulinum toxin type A is a safe and effective treatment for primary axillary hyperhidrosis and produces high levels of patient satisfaction.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/21 alle ore 03:06:22